- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Kolodziej Discusses Personalized Medicine in Oncology
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting.
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting. Dr Kolodziej discussed the importance of understanding how the information on specific genetic mutations to tailor therapy that is optimal for each patient will be used. "I think the discussion about how to develop the necessary quantum of information that you need to prove that it actually works," said Dr Kolodziej "Because from a payer perspective clinical utility is going to be the most important thing."
This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
